1737. Cost-Effectiveness Analysis of Catch-Up Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine

BACKGROUND: A 20-valent pneumococcal vaccine (PCV20) was approved in April 2023 by the US FDA for use in children < 18 years of age. Routine use in infants consists of a 3-dose schedule followed by a booster dose between 12 and 15 months of age. In addition, a catch-up program for children previo...

Descripción completa

Detalles Bibliográficos
Autores principales: Rozenbaum, Mark, Huang, Liping, Perdrizet, Johnna, Cane, Alejandro D, Arguedas, Adriano, hayford, Kyla, Tort, Maria J, Chapman, Ruth, Snow, Vincenza, Chilson, Erica, Farkouh, Ray, Dillon-Murphy, Desmond
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677452/
http://dx.doi.org/10.1093/ofid/ofad500.1568

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677452/
http://dx.doi.org/10.1093/ofid/ofad500.1568

Ejemplares similares